Apothecary Pharma LLC
Has Apothecary Pharma LLC received an FDA warning letter about GLP-1 drugs?
Yes. FDA issued Apothecary Pharma LLC a warning letter naming semaglutide and tirzepatide, dated Dec 1, 2025, with the FDA subject line “Compounding Pharmacy/Adulterated Drug Products.” openFDA also lists 1 drug recall report for the firm naming tirzepatide.
FDA records in this index name Apothecary Pharma LLC from Dec 1, 2025 to Sep 24, 2026. It is listed on FDA’s registered 503B outsourcing facility list: Apothecary Pharma, LLC, Cary, NC.
- Names in FDA records
- Apothecary Pharma LLC; Apothecary Pharma, LLC
- Type named in FDA records
- Compounding pharmacy, 503B outsourcing facility
- FDA warning letters
- 1
- Drug recall reports
- 1
- Drugs named
- Semaglutide, Tirzepatide
- Latest record
- Sep 24, 2026
- 503B location
- Cary, NC
- 503B last inspection
- Sep 2, 2026
- Form 483 issued
- Yes
- Action on last inspection
- Open
FDA warning letters
| Later letters FDA lists | Letter | |||
|---|---|---|---|---|
| Dec 1, 2025 | Compounding Pharmacy/Adulterated Drug Products | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
A warning letter states FDA’s view when it was issued; it is not a court finding, and the company may have responded since. The later-letters column repeats what FDA’s warning letter index lists for each letter.
FDA’s summary excerpts
- Dec 1, 2025: … drug products, such as Tirzepatide Injection 10 mg/mL and Semaglutide Injection 2.5 mg/mL, did not include the … Full letter
Drug recalls
| Record | |||||
|---|---|---|---|---|---|
| Sep 24, 2026 | Tirzepatide Injection, 18mg/mL, 4 mL Sterile Multi-Dose Vial, Rx only, Apothecary Pharma, LLC, 1913 Evans Road, Cary, NC 27513, NDC 85091-001-18. | Lack of Assurance of Sterility | Class II | Ongoing | D-0036-2027 |
FDA compounding inspections and actions
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists one facility under this exact legal name. These entries cover all of the facility’s compounding, not only GLP-1 drugs.
Apothecary Pharma LLC, Cary, NC (503B)
2 listed actions, including 1 Form 483 and 1 warning letter (2025).
| Document | |||
|---|---|---|---|
| Dec 1, 2025 | Warning letter | Warning Letter Issued 12/01/2025 | fda.gov |
| May 15, 2025 | Form 483 | 483 Issued 05/15/2025 | fda.gov |
A Form 483 lists investigator observations, not a final FDA determination. A warning letter states FDA’s view when it was issued, not a court finding; any close-out letter FDA lists is a row of its own.
Pharmacy pages with the same legal name, built from FDA’s 503B list and compounding inspections and actions page: Apothecary Pharma, LLC, Cary, NC.
FDA NDC listings
FDA’s NDC Directory files, read Nov 15, 2026, list 5 products naming tirzepatide under the labeler name “Apothecary Pharma LLC”, matched to this company page by exact name. Marketing categories as FDA gives them: OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) (5). The compounded product reports cover FDA reporting periods 2026-1 to 2026-1.
| Reporting periods | ||||||||
|---|---|---|---|---|---|---|---|---|
| 85091-001 | Tirzepatide | Tirzepatide Injection | INJECTION, SOLUTION | SUBCUTANEOUS | 18 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2026-1 | Compounded drugs |
| 85091-003 | Tirzepatide | Tirzepatide Injection | INJECTION, SOLUTION | SUBCUTANEOUS | 9 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2026-1 | Compounded drugs |
| 85091-004 | Tirzepatide and B12 | Tirzepatide Injection | INJECTION, SOLUTION | SUBCUTANEOUS | 17 mg/1 mL; 1 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2026-1 | Compounded drugs |
| 85091-005 | Tirzepatide and B12 | Tirzepatide Injection | INJECTION, SOLUTION | SUBCUTANEOUS | 8.5 mg/1 mL; 1 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2026-1 | Compounded drugs |
| 85091-006 | Tirzepatide and Glycine | Tirzepatide Injection | INJECTION, SOLUTION | SUBCUTANEOUS | 17 mg/1 mL; 5 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2026-1 | Compounded drugs |
FDA: “Outsourcing facilities that have elected to assign NDCs to their products provide FDA with a list of drugs they compounded during the previous six-month period upon initial registration and in June and December each year.” The compounded file gives no marketing dates; its reporting period is shown as FDA writes it.
FDA says: “Assignment of an NDC number does not in any way denote FDA approval of the product.” All GLP-1 NDC listings.
This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.
Sources
- FDA warning letter, Dec 1, 2025
- openFDA drug recall enforcement reports
- FDA Registered Outsourcing Facilities (503B)
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA warning letters (fda.gov full-text search)
- FDA National Drug Code Directory (download files)
- FDA: NDC product file definitions
- openFDA drug NDC endpoint (count cross-check)
Records last pulled Nov 15, 2026. Every entry links to the original public record.